Redeyes’ view on Dignitana is generally unchanged. The sales momentum continued in the quarter with ...
Gullberg & Jansson redovisade en minskad omsättning, EBIT och vinst jämfört med Q1’22.
Finepart (”Finepart” eller ”Bolaget”) har inlett år 2023 med stark leveransförmåga och orderingång, ...
Redeye provides an update post Embracers Q4 2022/23 results.
Redeye increases its forecasts and Base Case in ADDvise somewhat following raised financial targets,...
Mangold ser positivt på att ADDvise uppdaterat sina långsiktiga finansiella mål.
Återhållsam konsumentmarknad bidrar till en tuff inledning på året.
Syncro Group (alt. ”Koncernen”) presenterade nyligen sin Q1-rapport vilken visade hög tillväxt under...
Redeye comments on the positive results with BT-001 in the phase I study of solid tumours and update...
Redeye states that ChromoGenics Q1’23 report was overall better than expected despite soft top line.
Redeye's first comments on the Q1 report this morning.
Raute is set to complete its equity injections during the next few weeks.
Redeye comments on Sozap's partnership with Voodoo for Questopia; the deal not only reduces the risk...
Redeye comments on InDex Pharmaceuticals following its Q1 2023 report.
Redeye sees continued sales progression driven by the right underlying factors.
Steps taken to streamline operations and increase profitability Next major step is to outsource Orga...
Sales up 203% y-o-y, and 6% better than ABGSCe 1,000 patients treated signals 25% Catalyst q-o-q gro...
Läkemedelsbolaget EQL Pharma redovisade minskad nettoomsättning och EBIT i det fjärde kvartalet.
Reiterates 7.5% EBIT margin in Q4e (vs. 6.5% in Q1).
